[Renin-angiotensin system and urological cancers].

[1]  T. Dolley-Hitze,et al.  Récepteurs de type 1 à l’angiotensine-2 (AT1R) et cancers , 2013 .

[2]  Yang Zhao,et al.  Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. , 2012, Oncology reports.

[3]  R. Brekken,et al.  Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation , 2012, PloS one.

[4]  D. Khemasuwan,et al.  Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins , 2011, Cancer investigation.

[5]  E. Antonarakis,et al.  Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. , 2011, European journal of cancer.

[6]  D. Simon,et al.  Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. , 2011, The American journal of cardiology.

[7]  Tzeng-Ji Chen,et al.  Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. , 2011, The American journal of cardiology.

[8]  Karl Swedberg,et al.  Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals , 2011, Journal of hypertension.

[9]  Y. Neuzillet.  Les voies anti-angiogéniques du futur , 2011 .

[10]  R. Hannan,et al.  The renin–angiotensin system and cancer: old dog, new tricks , 2010, Nature Reviews Cancer.

[11]  N. Rioux-Leclercq,et al.  Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? , 2010, British Journal of Cancer.

[12]  Songbin Fu,et al.  Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF‐7 breast cancer cells survival via PI3‐kinase/Akt pathway , 2010, Journal of cellular physiology.

[13]  L. Mascitelli,et al.  Angiotensin-receptor blockade, cancer, and concerns. , 2010, The Lancet. Oncology.

[14]  C. Yeo,et al.  Blocking Angiotensin II Type 1 Receptor Triggers Apoptotic Cell Death in Human Pancreatic Cancer Cells , 2010, Pancreas.

[15]  D. Rowland,et al.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. , 2010, The Lancet. Oncology.

[16]  S. Nonogaki,et al.  Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma , 2010, Cancer Chemotherapy and Pharmacology.

[17]  P. Angus,et al.  Changes in the renin angiotensin system during the development of colorectal cancer liver metastases , 2010, BMC Cancer.

[18]  Hongwei Li,et al.  Angiotensin type 2 receptor–mediated apoptosis of human prostate cancer cells , 2009, Molecular Cancer Therapeutics.

[19]  G. Feldmann,et al.  The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer , 2009, Gut.

[20]  C. Yeo,et al.  Angiotensin II Regulates the Expression of Monocyte Chemoattractant Protein-1 in Pancreatic Cancer Cells , 2009, Journal of Gastrointestinal Surgery.

[21]  E. Kikuchi,et al.  Ets‐1 and hypoxia inducible factor‐1α inhibition by angiotensin II type‐1 receptor blockade in hormone‐refractory prostate cancer , 2009, The Prostate.

[22]  Narender Nath,et al.  Angiotensin II up‐regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor , 2009, The Prostate.

[23]  H. Yoshiji,et al.  Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. , 2009, Oncology reports.

[24]  J. Kinoshita,et al.  Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. , 2009, International journal of oncology.

[25]  R. Osieka,et al.  Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy , 2009, Journal of Cancer Research and Clinical Oncology.

[26]  E. Kikuchi,et al.  Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer. , 2009, Urology.

[27]  S. Cai,et al.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. , 2008, Chinese medical journal.

[28]  B. Segura-Pacheco,et al.  Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis , 2008, British Journal of Cancer.

[29]  R. Kreienberg,et al.  Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. , 2008, Gynecologic oncology.

[30]  Wei Huang,et al.  Angiotensin II Type 1 Receptor Antagonist Suppress Angiogenesis and Growth of Gastric Cancer Xenografts , 2008, Digestive Diseases and Sciences.

[31]  Stephen L. Brown,et al.  Differential Radiation Effect in Tumor and Normal Tissue after Treatment with Ramipril, an Angiotensin-Converting Enzyme Inhibitor , 2007, Radiation research.

[32]  H. Kawachi,et al.  Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. , 2007, The American journal of pathology.

[33]  C. Röcken,et al.  The Angiotensin II/Angiotensin II Receptor System Correlates with Nodal Spread in Intestinal Type Gastric Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[34]  Chai T. Saa,et al.  Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. , 2007, Journal of the American College of Surgeons.

[35]  E. Kikuchi,et al.  546: Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Prostate Cancer , 2007 .

[36]  E. Kikuchi,et al.  Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer , 2007, Human Cell.

[37]  H. Yoshiji,et al.  Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. , 2007, Oncology reports.

[38]  A. Ravaud.  [The mechanism of tumor angiogenesis]. , 2007, Progrès en urologie (Paris).

[39]  H. Qian,et al.  Type 1 angiotensin receptor pharmacology: Signaling beyond G proteins , 2006, Pharmacology & Therapeutics.

[40]  E. Kikuchi,et al.  Angiotensin II Type 1 Receptor Antagonist Candesartan as an Angiogenic Inhibitor in a Xenograft Model of Bladder Cancer , 2006, Clinical Cancer Research.

[41]  L. Hunyady,et al.  Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. , 2006, Molecular endocrinology.

[42]  Y. Kubota,et al.  Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer , 2005, International Journal of Clinical Oncology.

[43]  N. Rioux-Leclercq,et al.  [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer]. , 2005, Progrès en urologie (Paris).

[44]  C. Nahmias,et al.  Angiotensin receptors: a new role in cancer? , 2005, Trends in Endocrinology & Metabolism.

[45]  H. Chan,et al.  Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. , 2004, Cellular and molecular life sciences : CMLS.

[46]  HirokazuOhashi,et al.  Phosphatidylinositol 3-Kinase/Akt Regulates Angiotensin II–Induced Inhibition of Apoptosis in Microvascular Endothelial Cells by Governing Survivin Expression and Suppression of Caspase-3 Activity , 2004 .

[47]  H. Yoshiji,et al.  Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  Y. Nagashima,et al.  Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. , 2003, Molecular cancer therapeutics.

[49]  A. Muscella,et al.  Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells , 2003, Journal of cellular physiology.

[50]  A. Miyajima,et al.  Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. , 2002, Cancer research.

[51]  Y. Mori,et al.  Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. , 2001, Circulation research.

[52]  L. Murray,et al.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? , 1998, The Lancet.

[53]  D. Nicol,et al.  Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. , 1998, British Journal of Cancer.

[54]  R. A. Gomez,et al.  Differential expression of angiotensin II receptors during early renal morphogenesis. , 1997, The American journal of physiology.

[55]  T. Guzik,et al.  Novel therapeutic approaches in limiting oxidative stress and inflammation. , 2012, Current pharmaceutical biotechnology.

[56]  H. Sugiura,et al.  The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model. , 2011, Anticancer research.

[57]  B. Segura-Pacheco,et al.  Expression of AT 1 and AT 2 angiotensin receptors in astrocytomas is associated with poor prognosis , 2008 .

[58]  C. Yeo,et al.  Angiotensin II Induces Vascular Endothelial Growth Factor in Pancreatic Cancer Cells Through an Angiotensin II Type 1 Receptor and ERK1/2 Signaling , 2007, Journal of Gastrointestinal Surgery.

[59]  E. Kikuchi,et al.  Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer , 2007, The Prostate.

[60]  R. Harris,et al.  Tyrosine kinase inhibition affects type 1 angiotensin II receptor internalization. , 1999, Journal of receptor and signal transduction research.